Boston Scientific Company Profile (NYSE:BSX)

About Boston Scientific (NYSE:BSX)

Boston Scientific logoBoston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:BSX
  • CUSIP: 10113710
  • Web:
  • Market Cap: $37.33 billion
  • Outstanding Shares: 1,369,401,000
Average Prices:
  • 50 Day Moving Avg: $25.84
  • 200 Day Moving Avg: $23.86
  • 52 Week Range: $19.67 - $27.39
  • Trailing P/E Ratio: 87.37
  • Foreward P/E Ratio: 19.33
  • P/E Growth: 2.09
Sales & Book Value:
  • Annual Revenue: $8.58 billion
  • Price / Sales: 4.35
  • Book Value: $5.15 per share
  • Price / Book: 5.29
  • EBIDTA: $2.22 billion
  • Net Margins: 4.14%
  • Return on Equity: 23.70%
  • Return on Assets: 8.60%
  • Debt-to-Equity Ratio: 0.80%
  • Current Ratio: 0.90%
  • Quick Ratio: 0.64%
  • Average Volume: 6.76 million shs.
  • Beta: 1.06
  • Short Ratio: 1.76

Frequently Asked Questions for Boston Scientific (NYSE:BSX)

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) released its earnings results on Thursday, April, 27th. The company reported $0.29 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.30 by $0.01. The firm earned $2.16 billion during the quarter, compared to the consensus estimate of $2.08 billion. Boston Scientific had a return on equity of 23.70% and a net margin of 4.14%. The business's quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.28 EPS. View Boston Scientific's Earnings History.

When will Boston Scientific make its next earnings announcement?

Boston Scientific is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Boston Scientific.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific updated its FY17 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of $1.22-1.26 for the period, compared to the Thomson Reuters consensus estimate of $1.24. The company issued revenue guidance of $8.80-8.90 billion, compared to the consensus revenue estimate of $8.79 billion.Boston Scientific also updated its Q2 guidance to $0.30-0.32 EPS.

Where is Boston Scientific's stock going? Where will Boston Scientific's stock price be in 2017?

19 analysts have issued 1 year price objectives for Boston Scientific's stock. Their forecasts range from $25.00 to $33.00. On average, they anticipate Boston Scientific's stock price to reach $28.44 in the next year. View Analyst Ratings for Boston Scientific.

What are analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:

  • 1. According to Zacks Investment Research, "Boston Scientific posted a mixed first quarter, with earnings missing the Zacks Consensus Estimate and revenues ahead of the mark. While adverse foreign exchange continue to pose challenges, we are concerned with the company’s recent recall of one of its prime products, Lotus range of heart devices. Also dull defibrillator sale within core CRM continues to remain a drag for the overall growth. Accordingly, the share price trend, which remained below the broader industry over majority of the past three months on challenging economy, competitive landscape and currency headwinds, has continued to remain the same post the first quarter earnings release. Nevertheless, Boston Scientific is leaving no stone unturned to strengthen its core businesses and invest in innovations and global markets, which accounted for higher sales across all its geographies in the first quarter. The increased top line guidance for 2017 also buoys optimism." (5/1/2017)
  • 2. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)
  • 3. Northland Securities analysts commented, "The implications for Edwards now are a longer runway without BSX truly being on the market, potential questions arising about product design / reliability of the Lotus Valve. More importantly, Edwards now has a chance to pick up incremental share in Europe. We remain strong buyers of EW." (2/23/2017)

Who are some of Boston Scientific's key competitors?

Who owns Boston Scientific stock?

Boston Scientific's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (13.49%), BlackRock Inc. (6.99%), Vanguard Group Inc. (6.66%), Wellington Management Group LLP (4.96%), State Street Corp (4.21%) and Artisan Partners Limited Partnership (3.10%). Company insiders that own Boston Scientific stock include Charles J Dockendorff, Daniel J Brennan, David A Pierce, Ernest Mario, Jeffrey B Mirviss, John Bradley Sorenson, John E Abele, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Timothy A Pratt and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific.

Who sold Boston Scientific stock? Who is selling Boston Scientific stock?

Boston Scientific's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Bank of New York Mellon Corp, State Street Corp, Prudential Financial Inc., Marshall Wace LLP, Winslow Capital Management LLC, Boston Partners and American Century Companies Inc.. Company insiders that have sold Boston Scientific stock in the last year include David A Pierce, John Bradley Sorenson, Keith D Dawkins, Kevin J Ballinger, Michael F Mahoney, Michael P Phalen and Timothy A Pratt. View Insider Buying and Selling for Boston Scientific.

Who bought Boston Scientific stock? Who is buying Boston Scientific stock?

Boston Scientific's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Vanguard Group Inc., Renaissance Technologies LLC, TIAA CREF Investment Management LLC and Gotham Asset Management LLC. Company insiders that have bought Boston Scientific stock in the last two years include Charles J Dockendorff and John E Abele. View Insider Buying and Selling for Boston Scientific.

How do I buy Boston Scientific stock?

Shares of Boston Scientific can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Boston Scientific stock cost?

One share of Boston Scientific stock can currently be purchased for approximately $27.26.

Analyst Ratings

Consensus Ratings for Boston Scientific (NYSE:BSX) (?)
Ratings Breakdown: 5 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.74)
Consensus Price Target: $28.44 (4.32% upside)

Analysts' Ratings History for Boston Scientific (NYSE:BSX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017Goldman Sachs Group IncInitiated CoverageNeutral -> Neutral$28.00LowView Rating Details
4/28/2017Stifel NicolausBoost Price TargetBuy$28.00 -> $30.00LowView Rating Details
4/28/2017Cowen and CompanyBoost Price TargetOutperform$29.00 -> $31.00LowView Rating Details
4/28/2017Evercore ISIBoost Price TargetOutperform$26.50 -> $28.50LowView Rating Details
4/28/2017Oppenheimer Holdings Inc.Set Price TargetHold$27.00LowView Rating Details
4/27/2017Needham & Company LLCReiterated RatingBuy -> Buy$29.00 -> $30.00LowView Rating Details
4/12/2017GuggenheimReiterated RatingBuyLowView Rating Details
4/7/2017Jefferies Group LLCBoost Price TargetHold$26.00 -> $28.00LowView Rating Details
2/23/2017Northland SecuritiesReiterated RatingPositiveN/AView Rating Details
2/5/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
10/14/2016Royal Bank of CanadaReiterated RatingOutperform$28.00N/AView Rating Details
10/6/2016Citigroup IncBoost Price TargetBuy$28.00 -> $29.00N/AView Rating Details
9/1/2016ArgusUpgradeHold -> Buy$23.82 -> $33.00N/AView Rating Details
7/29/2016JPMorgan Chase & Co.Boost Price TargetOverweight$24.00 -> $27.00N/AView Rating Details
7/29/2016Credit Suisse Group AGReiterated RatingBuyN/AView Rating Details
7/29/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
7/29/2016WedbushBoost Price TargetNeutral$23.00 -> $25.00N/AView Rating Details
7/28/2016Benchmark Co.Boost Price TargetBuy$25.00 -> $31.00N/AView Rating Details
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00N/AView Rating Details
4/28/2016Barclays PLCBoost Price TargetOverweight$23.00 -> $25.00N/AView Rating Details
3/27/2016Morgan StanleyReiterated RatingOverweight$22.00N/AView Rating Details
3/25/2016Bank of America CorpReiterated RatingBuy$23.00N/AView Rating Details
3/18/2016Longbow ResearchInitiated CoverageBuyN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$22.00N/AView Rating Details
3/12/2016Deutsche Bank AGReiterated RatingHoldN/AView Rating Details
2/25/2016SunTrust Banks, Inc.Initiated CoverageBuy$21.00N/AView Rating Details
1/4/2016Sterne Agee CRTBoost Price TargetBuy$21.00 -> $22.50N/AView Rating Details
7/7/2015StephensInitiated CoverageOverweight$21.00N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for Boston Scientific (NYSE:BSX)
Earnings by Quarter for Boston Scientific (NYSE:BSX)
Earnings History by Quarter for Boston Scientific (NYSE:BSX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017$0.30$0.29$2.08 billion$2.16 billionViewN/AView Earnings Details
2/2/2017Q416$0.29$0.30$2.16 billion$2.19 billionViewListenView Earnings Details
10/26/2016Q316$0.27$0.27$2.07 billion$2.11 billionViewListenView Earnings Details
7/28/2016Q216$0.27$0.27$2.05 billion$2.13 billionViewListenView Earnings Details
4/27/2016Q116$0.24$0.28$1.91 billion$1.96 billionViewListenView Earnings Details
2/4/2016Q415$0.25$0.26$2.00 billion$1.98 billionViewListenView Earnings Details
10/28/2015Q315$0.23$0.24$1.86 billion$1.89 billionViewListenView Earnings Details
7/23/2015Q215$0.21$0.22$1.83 billion$1.84 billionViewListenView Earnings Details
4/28/2015Q115$0.21$0.21$1.78 billion$1.77 billionViewListenView Earnings Details
2/4/2015Q414$0.21$0.22$1.91 billion$1.89 billionViewListenView Earnings Details
10/22/2014Q314$0.20$0.20$1.82 billion$1.85 billionViewListenView Earnings Details
7/24/2014Q214$0.20$0.21$1.87 billion$1.87 billionViewListenView Earnings Details
4/29/2014Q114$0.18$0.20$1.80 billion$1.77 billionViewListenView Earnings Details
2/4/2014Q4$0.13$0.21$1.83 billion$1.84 billionViewListenView Earnings Details
10/24/2013Q313$0.09$0.17$1.73 billion$1.74 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.10$0.18$1.78 billion$1.81 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.09$0.16$1.79 billion$1.76 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.11$0.18$1.76 billion$1.82 billionViewListenView Earnings Details
10/18/2012$0.11($0.52)ViewN/AView Earnings Details
7/26/2012$0.08$0.17ViewN/AView Earnings Details
4/19/2012$0.13$0.15ViewN/AView Earnings Details
2/2/2012$0.08$0.07ViewN/AView Earnings Details
10/20/2011$0.09$0.15ViewN/AView Earnings Details
7/28/2011$0.08$0.17ViewN/AView Earnings Details
4/20/2011$0.04$0.01ViewN/AView Earnings Details
2/1/2011$0.09$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Boston Scientific (NYSE:BSX)
2017 EPS Consensus Estimate: $1.26
2018 EPS Consensus Estimate: $1.44
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175$0.29$0.31$0.30
Q2 20175$0.31$0.31$0.31
Q3 20176$0.29$0.32$0.31
Q4 20175$0.32$0.36$0.33
Q1 20181$0.34$0.34$0.34
Q2 20181$0.36$0.36$0.36
Q3 20182$0.34$0.36$0.35
Q4 20181$0.39$0.39$0.39
(Data provided by Zacks Investment Research)


Dividend History for Boston Scientific (NYSE:BSX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Boston Scientific (NYSE:BSX)
Insider Ownership Percentage: 1.31%
Institutional Ownership Percentage: 91.70%
Insider Trades by Quarter for Boston Scientific (NYSE:BSX)
Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)
Insider Trades by Quarter for Boston Scientific (NYSE:BSX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2017Kevin J. BallingerEVPSell28,864$26.14$754,504.96View SEC Filing  
5/1/2017Timothy A PrattEVPSell10,000$26.37$263,700.00View SEC Filing  
4/26/2017David A PierceSVPSell10,250$26.00$266,500.00View SEC Filing  
4/26/2017Michael P. PhalenEVPSell34,773$26.00$904,098.00View SEC Filing  
4/10/2017John Bradley SorensonSVPSell2,950$24.66$72,747.00View SEC Filing  
4/3/2017Timothy A PrattEVPSell10,000$24.87$248,700.00View SEC Filing  
3/29/2017Michael P. PhalenEVPSell79,045$24.55$1,940,554.75View SEC Filing  
3/3/2017David A PierceSVPSell25,012$25.01$625,550.12View SEC Filing  
3/3/2017Timothy A PrattEVPSell23,540$25.01$588,735.40View SEC Filing  
2/27/2017David A PierceSVPSell3,417$24.84$84,878.28View SEC Filing  
2/27/2017Timothy A PrattEVPSell4,832$24.84$120,026.88View SEC Filing  
2/7/2017Keith D DawkinsEVPSell80,783$25.21$2,036,539.43View SEC Filing  
1/9/2017David A PierceSVPSell10,232$22.24$227,559.68View SEC Filing  
1/9/2017Timothy A PrattEVPSell6,195$22.24$137,776.80View SEC Filing  
12/1/2016Timothy A PrattEVPSell26,726$20.48$547,348.48View SEC Filing  
8/11/2016John Bradley SorensonSVPSell2,500$23.90$59,750.00View SEC Filing  
8/1/2016Michael F MahoneyCEOSell44,400$24.44$1,085,136.00View SEC Filing  
8/1/2016Timothy A PrattEVPSell24,000$24.46$587,040.00View SEC Filing  
7/20/2016David A PierceSVPSell2,480$24.03$59,594.40View SEC Filing  
7/20/2016Michael P. PhalenEVPSell35,000$24.03$841,050.00View SEC Filing  
6/1/2016Michael F MahoneyCEOSell100,000$22.69$2,269,000.00View SEC Filing  
6/1/2016Timothy A PrattEVPSell24,229$22.66$549,029.14View SEC Filing  
5/11/2016John Bradley SorensonSVPSell2,800$22.15$62,020.00View SEC Filing  
5/10/2016Keith D DawkinsEVPSell80,000$22.15$1,772,000.00View SEC Filing  
5/6/2016Jeffrey B MirvissSVPSell24,659$21.94$541,018.46View SEC Filing  
5/3/2016Joseph Michael FitzgeraldEVPSell79,960$21.81$1,743,927.60View SEC Filing  
5/2/2016Michael F MahoneyCEOSell100,000$22.12$2,212,000.00View SEC Filing  
5/2/2016Timothy A PrattEVPSell24,000$21.93$526,320.00View SEC Filing  
4/27/2016Kevin J BallingerSVPSell111,807$21.62$2,417,267.34View SEC Filing  
4/27/2016Timothy A PrattEVPSell39,927$21.40$854,437.80View SEC Filing  
4/4/2016Jeffrey B MirvissSVPSell18,422$19.00$350,018.00View SEC Filing  
4/1/2016Michael F MahoneyCEOSell100,000$18.90$1,890,000.00View SEC Filing  
4/1/2016Timothy A PrattEVPSell24,000$18.73$449,520.00View SEC Filing  
3/11/2016Kevin J BallingerSVPSell16,705$18.00$300,690.00View SEC Filing  
3/8/2016Karen PrangeSVPSell14,747$17.27$254,680.69View SEC Filing  
3/2/2016Michael P. PhalenEVPSell10,665$17.17$183,118.05View SEC Filing  
3/1/2016Michael F MahoneyCEOSell100,000$16.96$1,696,000.00View SEC Filing  
3/1/2016Timothy A PrattEVPSell15,068$16.97$255,703.96View SEC Filing  
2/29/2016Kevin J. BallingerSVPSell2,114$17.17$36,297.38View SEC Filing  
2/29/2016Michael P. PhalenEVPSell1,819$17.19$31,268.61View SEC Filing  
2/25/2016Daniel J BrennanCFOSell103,211$17.22$1,777,293.42View SEC Filing  
2/25/2016Kevin J. BallingerSVPSell1,903$17.48$33,264.44View SEC Filing  
2/25/2016Michael P. PhalenEVPSell34,106$17.28$589,351.68View SEC Filing  
2/17/2016Kevin J. BallingerSVPSell7,616$17.37$132,289.92View SEC Filing  
2/12/2016Charles J DockendorffDirectorBuy30,000$16.49$494,700.00View SEC Filing  
2/8/2016Karen PrangeSVPSell6,216$16.05$99,766.80View SEC Filing  
1/8/2016Timothy A PrattEVPSell7,160$17.67$126,517.20View SEC Filing  
1/7/2016Kevin J BallingerSVPSell19,059$17.73$337,916.07View SEC Filing  
1/5/2016Jeffrey B MirvissSVPSell9,953$18.00$179,154.00View SEC Filing  
12/1/2015Timothy A. PrattEVPSell24,000$18.43$442,320.00View SEC Filing  
11/16/2015Ernest MarioDirectorSell125,000$17.63$2,203,750.00View SEC Filing  
11/9/2015John Bradley SorensonSVPSell4,469$18.68$83,480.92View SEC Filing  
11/9/2015Joseph Michael FitzgeraldEVPSell26,220$18.58$487,167.60View SEC Filing  
11/5/2015Timothy A PrattEVPSell19,598$19.00$372,362.00View SEC Filing  
10/28/2015Jeffrey B MirvissSVPSell9,492$18.00$170,856.00View SEC Filing  
10/28/2015Timothy A PrattEVPSell3,500$18.00$63,000.00View SEC Filing  
10/5/2015Timothy A PrattEVPSell3,500$17.34$60,690.00View SEC Filing  
10/1/2015Timothy A. PrattEVPSell17,000$16.33$277,610.00View SEC Filing  
8/21/2015John E AbeleDirectorBuy200,000$16.77$3,354,000.00View SEC Filing  
8/19/2015John E AbeleDirectorBuy200,000$17.48$3,496,000.00View SEC Filing  
8/17/2015John E AbeleDirectorBuy100,000$17.50$1,750,000.00View SEC Filing  
7/7/2015Karen PrangeSVPSell17,456$17.66$308,272.96View SEC Filing  
5/29/2015Maulik NanavatySVPSell71,558$18.52$1,325,254.16View SEC Filing  
5/28/2015Wendy CarruthersSVPSell42,281$17.91$757,252.71View SEC Filing  
5/18/2015Ernest MarioDirectorSell50,000$18.09$904,500.00View SEC Filing  
5/14/2015John E SununuDirectorSell10,000$17.87$178,700.00View SEC Filing  
5/11/2015John Bradley SorensonSVPSell8,735$17.49$152,775.15View SEC Filing  
3/20/2015David A PierceSVPSell18,050$18.00$324,900.00View SEC Filing  
3/20/2015Michael P PhalenEVPSell46,085$17.94$826,764.90View SEC Filing  
3/16/2015Michael P PhalenEVPSell30,022$17.18$515,777.96View SEC Filing  
3/13/2015John Bradley SorensonSVPSell3,830$16.84$64,497.20View SEC Filing  
3/9/2015David A PierceSVPSell2,561$16.54$42,358.94View SEC Filing  
3/3/2015David A PierceSVPSell8,983$16.79$150,824.57View SEC Filing  
3/3/2015Michael P PhalenEVPSell12,768$16.79$214,374.72View SEC Filing  
2/27/2015David A PierceSVPSell19,046$16.80$319,972.80View SEC Filing  
2/27/2015Michael P PhalenEVPSell1,819$16.80$30,559.20View SEC Filing  
2/19/2015David A PierceSVPSell11,958$16.46$196,828.68View SEC Filing  
2/19/2015Michael P PhalenEVPSell13,188$16.44$216,810.72View SEC Filing  
2/10/2015Joseph Michael FitzgeraldEVPSell61,208$14.66$897,309.28View SEC Filing  
2/9/2015David A PierceSVPSell5,000$14.66$73,300.00View SEC Filing  
2/6/2015Kevin J BallingerSVPSell21,408$15.06$322,404.48View SEC Filing  
1/20/2015Michael P PhalenEVPSell10,000$14.54$145,400.00View SEC Filing  
1/8/2015David A PierceSVPSell18,612$14.31$266,337.72View SEC Filing  
1/8/2015Michael P PhalenEVPSell27,589$14.31$394,798.59View SEC Filing  
1/5/2015Michael P PhalenEVPSell10,000$13.75$137,500.00View SEC Filing  
12/10/2014Karen PrangeSVPSell19,753$12.64$249,677.92View SEC Filing  
12/8/2014David A PierceSVPSell5,000$12.90$64,500.00View SEC Filing  
12/1/2014Ernest MarioDirectorSell10,000$12.96$129,600.00View SEC Filing  
11/28/2014Michael F MahoneyCEOBuy11,700$12.89$150,813.00View SEC Filing  
11/10/2014Edward J LudwigDirectorBuy10,000$13.38$133,800.00View SEC Filing  
11/5/2014John E SununuDirectorSell8,997$13.38$120,379.86View SEC Filing  
11/3/2014Ernest MarioDirectorSell10,000$13.30$133,000.00View SEC Filing  
10/8/2014Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
9/2/2014Ernest MarioDirectorSell10,000$12.60$126,000.00View SEC Filing  
8/15/2014Michael P PhalenEVPSell11,471$12.58$144,305.18View SEC Filing  
8/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
7/30/2014David A PierceSVPSell157$12.97$2,036.29View SEC Filing  
7/15/2014Michael P PhalenEVPSell67,500$13.04$880,200.00View SEC Filing  
7/1/2014Ernest MarioDirectorSell10,000$12.95$129,500.00View SEC Filing  
6/16/2014Michael P PhalenEVPSell13,500$13.02$175,770.00View SEC Filing  
6/2/2014Ernest MarioDirectorSell10,000$12.88$128,800.00View SEC Filing  
5/15/2014Michael PhalenEVPSell13,500$12.76$172,260.00View SEC Filing  
5/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
4/15/2014Michael PhalenEVPSell13,500$13.25$178,875.00View SEC Filing  
4/1/2014Ernest MarioDirectorSell10,000$13.55$135,500.00View SEC Filing  
3/17/2014Michael PhalenEVPSell13,500$13.05$176,175.00View SEC Filing  
3/6/2014David PierceSVPSell5,316$13.44$71,447.04View SEC Filing  
3/6/2014Michael PhalenEVPSell7,281$13.44$97,856.64View SEC Filing  
2/27/2014David PierceSVPSell2,057$13.29$27,337.53View SEC Filing  
2/27/2014Michael PhalenEVPSell3,166$13.29$42,076.14View SEC Filing  
2/21/2014David PierceSVPSell3,199$13.22$42,290.78View SEC Filing  
2/21/2014Michael PhalenEVPSell3,222$13.22$42,594.84View SEC Filing  
2/18/2014Michael PhalenEVPSell13,500$13.30$179,550.00View SEC Filing  
2/13/2014Kristina JohnsonDirectorSell18,000$13.01$234,180.00View SEC Filing  
2/6/2014Ernest MarioDirectorSell17,104$12.80$218,931.20View SEC Filing  
2/3/2014Ernest MarioDirectorSell10,000$13.19$131,900.00View SEC Filing  
1/6/2014Ernest MarioDirectorSell10,000$12.50$125,000.00View SEC Filing  
12/26/2013Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
11/26/2013Jeffrey CapelloCFOSell85,106$11.82$1,005,952.92View SEC Filing  
11/11/2013Jeffrey MirvissSVPSell26,000$11.91$309,660.00View SEC Filing  
8/29/2013Jeffrey CapelloCFOSell525,000$10.68$5,607,000.00View SEC Filing  
8/16/2013Joseph Michael FitzgeraldSVPSell9,202$11.02$101,406.04View SEC Filing  
8/14/2013Kevin BallingerSVPSell38,171$11.28$430,568.88View SEC Filing  
5/31/2013Jeffrey B MirvissSVPSell10,941$9.37$102,517.17View SEC Filing  
5/30/2013Wendy CarruthersSVPSell25,001$9.16$229,009.16View SEC Filing  
5/29/2013Nelda J ConnorsDirectorSell24,116$9.17$221,143.72View SEC Filing  
5/6/2013Ernest MarioDirectorBuy30,000$7.76$232,800.00View SEC Filing  
11/13/2012Nj Nicholas JrDirectorBuy20,000$5.28$105,600.00View SEC Filing  
11/9/2012Nj Nicholas JrDirectorBuy25,000$5.17$129,250.00View SEC Filing  
8/6/2012Ernest MarioDirectorBuy32,000$5.29$169,280.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Boston Scientific (NYSE:BSX)
Latest Headlines for Boston Scientific (NYSE:BSX)
DateHeadline logoBoston Scientific (BSX) BT Study on Asthma Results Positive - May 25 at 5:23 PM logoAnalysts’ Recommendations for Abbott Laboratories in May 2017 - May 25 at 5:23 PM logoBRIEF-Boston Scientific announces positive outcomes from prospective study of bronchial thermoplasty - May 24 at 10:48 AM logoBoston Scientific Announces Positive Outcomes From Prospective Study Of Bronchial Thermoplasty - May 24 at 10:47 AM logoBoston Scientific In Buy Zone, Gets Stock Rating Upgrade - May 19 at 3:58 PM logoBoston Scientific's Symetis Buyout Boosts Structural Heart - May 19 at 9:00 AM logoKevin J. Ballinger Sells 28,864 Shares of Boston Scientific Co. (BSX) Stock - May 18 at 7:26 PM logoBoston Scientific to Participate in 2017 UBS Global Healthcare Conference - May 17 at 9:07 PM logoBoston Scientific Hits a 52-Week High on Solid Prospects - Nasdaq - May 17 at 11:21 AM logoBoston Scientific Co. (BSX) Research Coverage Started at Goldman Sachs Group Inc - May 16 at 8:56 PM logoBoston's Heart Valve Wins In Face-Off Trial With Rival Medtronic - May 16 at 4:08 PM logoBoston Scientific Closes Symetis Acquisition - PR Newswire (press release) - May 16 at 9:17 AM logoBoston Scientific Closes Symetis Acquisition - May 16 at 9:17 AM logoThe Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year - May 16 at 9:17 AM logoBRIEF-Boston Scientific says positive European registry results for WATCHMAN left atrial appendage closure device - May 12 at 8:30 PM logoNew Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Traditional Clinically-Reported Endpoints - May 12 at 8:30 PM logoBoston Scientific Announces Positive European Registry Results For WATCHMAN™ Left Atrial Appendage Closure Device - May 12 at 8:30 PM logoBoston Scientific Co. (BSX) Expected to Announce Quarterly Sales of $2.21 Billion - May 12 at 4:52 PM logoBoston Scientific Co. (BSX) Receives Consensus Rating of "Buy" from Analysts - May 12 at 1:14 PM logoBoston Scientific Receives U.S. FDA Approval For Resonate™ Family Of High-Voltage Devices - PR Newswire (press release) - May 11 at 9:39 PM logoBoston Scientific S-ICD System Demonstrates Positive Clinical Outcomes in the Largest Prospective Study of 'Real-World' Patients - May 11 at 4:37 PM logoBoston Scientific (BSX) Granted FDA Approval for Resonate ICD and CRT-D Systems - - May 10 at 8:39 AM logoBoston Scientific Announces Schedule of Presentations at EuroPCR 2017 - PR Newswire (press release) - May 10 at 8:39 AM logoBoston Scientific Announces Schedule of Presentations at EuroPCR 2017 - May 10 at 8:39 AM logoBlog Coverage: FDA Approves Boston Scientific's Resonate Family of High-Voltage Devices - May 10 at 8:39 AM logo Brokerages Expect Boston Scientific Co. (BSX) Will Announce Earnings of $0.31 Per Share - May 10 at 8:06 AM logoBoston Scientific Sees Unusually Large Options Volume (BSX) - May 10 at 7:20 AM logoBehind Boston Scientific’s Recent Stock Performance - May 9 at 4:03 PM logoBRIEF-Boston Scientific receives FDA approval for resonate family of high-voltage devices - May 9 at 8:37 AM logoFDA OKs Boston Sci's Resonate family of high-voltage devices - May 9 at 8:37 AM logoBoston Scientific Receives U.S. FDA Approval For Resonate™ Family Of High-Voltage Devices - May 9 at 8:37 AM logoInside Boston Scientific’s Acquisition of Symetis: The Must-Know Details - May 9 at 8:37 AM logoUnderstanding Boston Scientific’s Key Growth Drivers for MedSurg - May 8 at 3:58 PM logoYour Highlights of Boston Scientific’s 1Q17 Earnings - May 8 at 10:22 AM logoWhat Dragged down BSX’s 1Q17 Margins? - May 8 at 10:22 AM logoInside the Latest Analyst Recommendations for Boston Scientific - May 5 at 9:06 PM logoBoston Scientific is the 2nd biggest dealmaker in medtech since 2012 - May 4 at 4:11 PM logoBoston Scientific Announces Scheduled Presentations at Heart Rhythm Society 2017 - May 3 at 7:16 PM logoInsider Selling: Boston Scientific Co. (BSX) EVP Sells 10,000 Shares of Stock - May 2 at 9:54 PM logoBoston Scientific (BSX) Earning Somewhat Positive Press Coverage, AlphaOne Reports - May 2 at 5:10 PM logoBoston Scientific Co. (BSX) Raised to "Hold" at Zacks Investment Research - May 1 at 11:04 PM logoFY2017 Earnings Estimate for Boston Scientific Co. (BSX) Issued By Wedbush - May 1 at 10:55 AM logoBoston Scientific Co. Forecasted to Post FY2017 Earnings of $1.25 Per Share (BSX) - May 1 at 10:54 AM logoBoston Scientific to Participate in Bank of America Merrill Lynch 2017 Healthcare Conference - May 1 at 9:01 AM logoBoston Scientific Co. to Post Q2 2017 Earnings of $0.31 Per Share, Jefferies Group Forecasts (BSX) - May 1 at 8:24 AM logoBoston Scientific (BSX) Earning Favorable News Coverage, Analysis Shows - April 29 at 3:53 PM logoBoston Scientific Co. (BSX) Given a $27.00 Price Target at Oppenheimer Holdings Inc. - April 29 at 12:46 PM logoStifel Nicolaus Reaffirms "Buy" Rating for Boston Scientific Co. (BSX) - April 28 at 6:38 PM logoEvercore ISI Reiterates Outperform Rating for Boston Scientific Co. (BSX) - April 28 at 5:48 PM logoBoston Scientific's (BSX) "Outperform" Rating Reaffirmed at Cowen and Company - April 28 at 5:48 PM



Boston Scientific (BSX) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff